Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This study involves people who have schizophrenia or schizoaffective disorder who are
currently taking antipsychotic medications. Some antipsychotic medications may cause weight
gain and may increase the risk of diabetes mellitus and heart disease.The purpose of this
study is to find out what happens if another medication (ramelteon) is used along with your
antipsychotic medication. We want to find out whether doing this will:
- Change the way your body breaks down fat and sugar.
- Affect your waist size, stomach fat and triglycerides (a type of fat in your blood).
- Improve how your body responds to insulin.
- Affect your quality of sleep.
- Reduce movement disturbances Ramelteon is approved by the U.S. Food and Drug
Administration (FDA) to treat people that have difficulty falling asleep. It is not
approved for such things as affecting waist size or improving how the body breaks down
fat and sugar. Its use in this study is investigational.